|
1
|
Pelcovits A and Niroula R: Acute myeloid
leukemia: A review. R I Med J (2013). 103:38–40. 2020.PubMed/NCBI
|
|
2
|
Yi M, Li A, Zhou L, Chu Q, Song Y and Wu
K: The global burden and attributable risk factor analysis of acute
myeloid leukemia in 195 countries and territories from 1990 to
2017: Estimates based on the global burden of disease study 2017. J
Hematol Oncol. 13(72)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chennamadhavuni A, Lyengar V and
Shimanovsky A: Leukemia. In: StatPearls [Internet]. Treasure Island
(FL), StatPearls Publishing; 2022.
|
|
4
|
Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ
and Kook H: Improvement of treatment outcome over 2 decades in
children with acute myeloid leukemia. Blood Res. 53:25–34.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Herzig RH, Wolff SN, Lazarus HM, Phillips
GL, Karanes C and Herzig GP: High-dose cytosine arabinoside therapy
for refractory leukemia. Blood. 62:361–369. 1983.PubMed/NCBI
|
|
6
|
Hwang WL, Young JH, Gau JP, Hu HT and Tsai
YT: DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose
Ara-C for remission induction and consolidation treatment of adult
patients with acute myeloid leukemia. Am J Clin Oncol. 15:531–534.
1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gessner A, Thomas M, Castro PG, Büchler L,
Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J and
Heidenreich O: Leukemic fusion genes MLL/AF4 and AML1/MTG8 support
leukemic self-renewal by controlling expression of the telomerase
subunit TERT. Leukemia. 24:1751–1759. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nakamura H, Kuriyama K, Sadamori N, Mine
M, Itoyama T, Sasagawa I, Matsumoto K, Tsuji Y, Asou N, Kageyama
SI, et al: Morphological subtyping of acute myeloid leukemia with
maturation (AML-M2): Homogeneous pink-colored cytoplasm of mature
neutrophils is most characteristic of AML-M2 with t(8;21).
Leukemia. 11:651–655. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jirasek MA and Herrington JD: Cytarabine
syndrome despite corticosteroid premedication in an adult
undergoing induction treatment for acute myelogenous leukemia. J
Oncol Pharm Pract. 22:795–800. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Moore AS, Kearns PR, Knapper S, Pearson AD
and Zwaan CM: Novel therapies for children with acute myeloid
leukaemia. Leukemia. 27:1451–1460. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schweitzer J, Zimmermann M, Rasche M, von
Neuhoff C, Creutzig U, Dworzak M, Reinhardt D and Klusmann JH:
Improved outcome of pediatric patients with acute megakaryoblastic
leukemia in the AML-BFM 04 trial. Ann Hematol. 94:1327–1336.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rubnitz JE, Pounds S, Cao X, Jenkins L,
Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Campana D and Inaba
H: Treatment outcome in older patients with childhood acute myeloid
leukemia. Cancer. 118:6253–6259. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kaspers GJ, Zimmermann M, Reinhardt D,
Gibson BE, Tamminga RY, Aleinikova O, Armendariz H, Dworzak M, Ha
SY, Hasle H, et al: Improved outcome in pediatric relapsed acute
myeloid leukemia: Results of a randomized trial on liposomal
daunorubicin by the International BFM Study Group. J Clin Oncol.
31:599–607. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Abrahamsson J, Forestier E, Heldrup J,
Jahnukainen K, Jónsson OG, Lausen B, Palle J, Zeller B and Hasle H:
Response-guided induction therapy in pediatric acute myeloid
leukemia with excellent remission rate. J Clin Oncol. 29:310–315.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rubnitz JE: Current management of
childhood acute myeloid leukemia. Paediatr Drugs. 19:1–10.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pollard JA, Guest E, Alonzo TA, Gerbing
RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S,
Raimondi SC, et al: Gemtuzumab ozogamicin improves event-free
survival and reduces relapse in pediatric KMT2A-Rearranged AML:
Results from the phase III Children's Oncology Group Trial
AAML0531. J Clin Oncol. 39:3149–3160. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Garg A, Ganguly S, Vishnubhatla S, Chopra
A and Bakhshi S: Outpatient ADE (cytarabine, daunorubicin, and
etoposide) is feasible and effective for the first relapse of
pediatric acute myeloid leukemia: A prospective, phase II study.
Pediatr Blood Cancer. 67(e28404)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Willemze R, Suciu S, Meloni G, Labar B,
Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, et
al: High-dose cytarabine in induction treatment improves the
outcome of adult patients younger than age 46 years with acute
myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial. J Clin
Oncol. 32:219–228. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li W, Gong X, Sun M, Zhao X, Gong B, Wei
H, Mi Y and Wang J: High-dose cytarabine in acute myeloid leukemia
treatment: A systematic review and meta-analysis. PLoS One.
9(e110153)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Padilha SL, Souza EJ, Matos MC and Domino
NR: Acute myeloid leukemia: Survival analysis of patients at a
university hospital of Parana. Rev Bras Hematol Hemoter. 37:21–27.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wu D, Duan C, Chen L and Chen S: Efficacy
and safety of different doses of cytarabine in consolidation
therapy for adult acute myeloid leukemia patients: A network
meta-analysis. Sci Rep. 7(9509)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jastaniah W, Al Ghemlas I, Al Daama S,
Ballourah W, Bayoumy M, Al-Anzi F, Al Shareef O, Alsultan A, Abrar
MB and Al Sudairy R: Clinical characteristics and outcome of
childhood de novo acute myeloid leukemia in Saudi Arabia: A
multicenter SAPHOS leukemia group study. Leuk Res. 49:66–72.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pession A, Masetti R, Rizzari C, Putti MC,
Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C,
et al: Results of the AIEOP AML 2002/01 multicenter prospective
trial for the treatment of children with acute myeloid leukemia.
Blood. 122:170–178. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Creutzig U, Zimmermann M, Dworzak MN,
Ritter J, Schellong G and Reinhardt D: Development of a curative
treatment within the AML-BFM studies. Klin Padiatr. 225 (Suppl
1):S79–S86. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Creutzig U, Zimmermann M, Bourquin JP,
Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B,
Lehrnbecher T, von Neuhoff C, et al: Randomized trial comparing
liposomal daunorubicin with idarubicin as induction for pediatric
acute myeloid leukemia: Results from Study AML-BFM 2004. Blood.
122:37–43. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cooper TM, Franklin J, Gerbing RB, Alonzo
TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci
RJ, et al: AAML03P1, a pilot study of the safety of gemtuzumab
ozogamicin in combination with chemotherapy for newly diagnosed
childhood acute myeloid leukemia: A report from the Children's
Oncology Group. Cancer. 118:761–769. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Arber DA: The 2016 WHO classification of
acute myeloid leukemia: What the practicing clinician needs to
know. Semin Hematol. 56:90–95. 2019.PubMed/NCBI View Article : Google Scholar
|
